RxDoctor Payments Data

Hari Saini, MD

Cardiovascular Disease · Fayetteville, NCNPI 1649269275

Payments from drug & device makers

$38,087in general payments, 2019–2025

Across 211 payments — averaging $180.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$34K
  • Cardiovascular Systems Inc.$858
  • Amgen$368
  • Pfizer$308
  • Johnson & Johnson$294
  • Merck$228
  • plus $2K from 31 others

What the payments were for

  • Speaking & faculty fees$3001%
  • Travel & lodging$5341%
  • Food & beverage$3,5979%
  • Education$3,2128%
  • Other$30,44380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,087 in reported general payments places this provider in the 80th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,119,177
Medicare patients
1,039
Services billed
5,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban192$189,797
XareltoRivaroxaban92$79,769
EntrestoSacubitril/Valsartan86$75,456
Repatha SureclickEvolocumab17$26,077
BrilintaTicagrelor26$16,552
Metoprolol Succinate395$4,533
Dabigatran EtexilateDabigatran Etexilate Mesylate20$3,541
Diltiazem 24hr Er (Cd)Diltiazem Hcl93$2,443
ClopidogrelClopidogrel Bisulfate312$2,410
Ranolazine ErRanolazine35$1,953
Varenicline Tartrate16$1,932
Atorvastatin Calcium214$1,882
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide11$1,232
Rosuvastatin Calcium106$1,177
Losartan Potassium129$870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$308$189,797192 claims
Johnson & JohnsonXarelto$294$79,76992 claims
NovartisEntresto$147$75,45686 claims
AstraZenecaBrilinta$116$16,55226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →